{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T09:26:21Z","timestamp":1718961981354},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DHPS"],"DOI":"10.2147\/dhps.s28822","type":"journal-article","created":{"date-parts":[[2013,2,26]],"date-time":"2013-02-26T03:53:24Z","timestamp":1361850804000},"page":"37","source":"Crossref","is-referenced-by-count":14,"title":["Oral available agents in the treatment of relapsing remitting multiple sclerosis an overview of merits and culprits"],"prefix":"10.2147","author":[{"given":"Jan","family":"Th\u00f6ne","sequence":"first","affiliation":[]},{"family":"Ellrichmann","sequence":"additional","affiliation":[]}],"member":"301","published-online":{"date-parts":[[2013,2]]},"container-title":["Drug, Healthcare and Patient Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=15306","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,10,30]],"date-time":"2016-10-30T22:13:26Z","timestamp":1477865606000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.dovepress.com\/oral-available-agents-in-the-treatment-of-relapsing-remitting-multiple-peer-reviewed-article-DHPS"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/dhps.s28822","relation":{},"ISSN":["1179-1365"],"issn-type":[{"value":"1179-1365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}